Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety and PK of RO6953958 in Healthy Men
NCT04475848Phase 1Completed
- Sponsor
- Roche
- Start
- Jul 2020
- Primary completion
- Feb 2022
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of RO6953958 in Autism Spectrum Disorder (ASD) (5 arms), sponsored by Roche. Primary endpoints: Percentage of Participants With Adverse Events up to 8 weeks and Number of Participants With Post-baseline Suicide Risk (C-SSRS) up to 8 weeks. Started Jul 2020; status: completed.
02
Drugs
RO6953958
03
Conditions
Autism Spectrum Disorder (ASD)
Beyond the preview
Go deeper on NCT04475848.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04475848.